Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Slac2-c Inhibitors

Slac2-c inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the protein Slac2-c, also known as synaptotagmin-like protein 2-c. Slac2-c is a member of the Rab27A effector family and plays an essential role in vesicle transport and membrane trafficking within cells. It functions by interacting with Rab27A, a small GTPase involved in the regulation of vesicle docking and fusion, especially in secretory pathways. Slac2-c acts as an adaptor protein that connects Rab27A with molecular motors such as myosin, facilitating the transport of vesicles along actin filaments toward their target membranes. Inhibitors of Slac2-c work by binding to critical regions of the protein, disrupting its interaction with Rab27A or other molecular components, thus interfering with its role in vesicular trafficking.

The design and study of Slac2-c inhibitors are based on a thorough understanding of the protein's structure and its interactions with other molecules involved in vesicle transport. Researchers typically employ structural biology techniques such as molecular docking, X-ray crystallography, and computational modeling to identify potential binding sites on Slac2-c that are critical for its function. Inhibitors are developed to specifically bind to these sites, blocking the protein's ability to mediate vesicle transport. These inhibitors are evaluated using various biochemical assays to measure their binding affinity, specificity, and inhibitory effects on vesicle movement. By inhibiting Slac2-c, researchers can gain insights into the mechanisms underlying vesicle trafficking, membrane fusion, and how these processes contribute to cellular organization and function. The study of Slac2-c inhibitors expands the understanding of intracellular transport systems, revealing the importance of adaptor proteins like Slac2-c in coordinating vesicular dynamics and cellular cargo movement.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt

94825-44-2sc-202639
10 mg
$465.00
(0)

Activates GTPases like Rab27, potentially disrupting its interaction with Slac2-c.

Nocodazole

31430-18-9sc-3518B
sc-3518
sc-3518C
sc-3518A
5 mg
10 mg
25 mg
50 mg
$59.00
$85.00
$143.00
$247.00
38
(2)

Disrupts microtubules which can affect granule transport and indirectly affect Slac2-c mediated functions.

Latrunculin A, Latrunculia magnifica

76343-93-6sc-202691
sc-202691B
100 µg
500 µg
$265.00
$815.00
36
(2)

Disrupts actin filaments which can affect the cytoskeleton's interaction with secretory granules.

ML 141

71203-35-5sc-362768
sc-362768A
5 mg
25 mg
$137.00
$512.00
7
(1)

Inhibits Cdc42, a small GTPase which could indirectly affect Slac2-c mediated granule transport.

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$31.00
$53.00
$124.00
$374.00
25
(3)

Disrupts the Golgi apparatus and vesicle transport, potentially affecting Slac2-c's role in exocytosis.

Dynamin Inhibitor I, Dynasore

304448-55-3sc-202592
10 mg
$89.00
44
(2)

Inhibits dynamin and can impact vesicle trafficking and fusion events.

Neomycin sulfate

1405-10-3sc-3573
sc-3573A
1 g
5 g
$27.00
$35.00
20
(5)

Disrupts phospholipid binding on the membrane which could interfere with vesicle fusion processes.

SecinH3

853625-60-2sc-203260
5 mg
$278.00
6
(1)

Inhibits cytohesin ARF GEPs, potentially impacting vesicle transport.

YM201636

371942-69-7sc-204193
5 mg
$217.00
6
(1)

Inhibits PIKfyve, affecting vesicle trafficking and potentially Slac2-c mediated processes.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

PI3 kinase inhibitor which can affect vesicle trafficking indirectly.